These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Efficacy and augmentation during 6 months of double-blind pramipexole for restless legs syndrome. Högl B; Garcia-Borreguero D; Trenkwalder C; Ferini-Strambi L; Hening W; Poewe W; Brenner SS; Fraessdorf M; Busse M; Albrecht S; Allen RP Sleep Med; 2011 Apr; 12(4):351-60. PubMed ID: 21354368 [TBL] [Abstract][Full Text] [Related]
4. Exercise dependence induced by pramipexole in Parkinson's Disease-a case report. Vitale C; Santangelo G; Verde F; Amboni M; Sorrentino G; Grossi D; Barone P Mov Disord; 2010 Dec; 25(16):2893-4. PubMed ID: 20687190 [No Abstract] [Full Text] [Related]
5. Impact of pramipexole on the onset of levodopa-related dyskinesias. Constantinescu R; Romer M; McDermott MP; Kamp C; Kieburtz K; Mov Disord; 2007 Jul; 22(9):1317-9. PubMed ID: 17534955 [TBL] [Abstract][Full Text] [Related]
6. Spontaneous unwelcome orgasms due to pramipexole and ropinirole. Kaut O; Asmus F; Paus S Mov Disord; 2012 Sep; 27(10):1327-8. PubMed ID: 22903628 [No Abstract] [Full Text] [Related]
8. Telogen effluvium associated with the dopamine agonist pramipexole in a 55-year-old woman with Parkinson's disease. Katz KA; Cotsarelis G; Gupta R; Seykora JT J Am Acad Dermatol; 2006 Nov; 55(5 Suppl):S103-4. PubMed ID: 17052518 [No Abstract] [Full Text] [Related]
9. [Pathological gambling associated with pramipexole use in Parkinson's disease]. Lester J; Gonzalez-Aleman G; Zuniga-Ramirez C; Diaz-Pascuali SP; Raina-Castellino GB; Micheli-Gould F Rev Neurol; 2006 Sep 1-15; 43(5):316-8. PubMed ID: 16941434 [No Abstract] [Full Text] [Related]
10. Panic attack-like episodes possibly induced by pramipexole in a patient with young-onset Parkinson's disease. de Cerqueira AC; Nardi AE J Neuropsychiatry Clin Neurosci; 2011; 23(3):E21. PubMed ID: 21948911 [No Abstract] [Full Text] [Related]
11. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson's disease. Perez Lloret S; Rascol O Expert Opin Pharmacother; 2010 Sep; 11(13):2221-30. PubMed ID: 20670197 [TBL] [Abstract][Full Text] [Related]
12. Controlled withdrawal of pramipexole after 6 months of open-label treatment in patients with restless legs syndrome. Trenkwalder C; Stiasny-Kolster K; Kupsch A; Oertel WH; Koester J; Reess J Mov Disord; 2006 Sep; 21(9):1404-10. PubMed ID: 16755554 [TBL] [Abstract][Full Text] [Related]
13. Risk factors for the development of pedal edema in patients using pramipexole. Kleiner-Fisman G; Fisman DN Arch Neurol; 2007 Jun; 64(6):820-4. PubMed ID: 17420306 [TBL] [Abstract][Full Text] [Related]
14. Pramipexole and gender identity disorder: expanding the phenotype of hypersexuality in Parkinson's disease. Odiyoor M; Kobylecki C; Hackett RJ; Silverdale MA; Kellett MW Mov Disord; 2009 Dec; 24(16):2434-5. PubMed ID: 19891000 [No Abstract] [Full Text] [Related]
15. [Pathologic gambling as an adverse effect of the treatment for Parkinson's disease]. Miranda M; Slachevsky A; Bustamante L; Pérez C Rev Med Chil; 2010 Apr; 138(4):521-2. PubMed ID: 20668805 [No Abstract] [Full Text] [Related]
17. A cup of coffee a day keeps dyskinesia away? Jenner P Mov Disord; 2013 Mar; 28(3):265-7. PubMed ID: 23447426 [No Abstract] [Full Text] [Related]
18. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Parkinson Study Group CALM Cohort Investigators Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655 [TBL] [Abstract][Full Text] [Related]
19. An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease. Lyons KE; Pahwa R Mov Disord; 2009 Oct; 24(14):2121-7. PubMed ID: 19768728 [TBL] [Abstract][Full Text] [Related]